期刊
ADVANCES IN THERAPY
卷 34, 期 4, 页码 848-853出版社
SPRINGER
DOI: 10.1007/s12325-017-0508-9
关键词
Anemia; Chronic kidney disease; Erythropoietin-stimulating agent; Dialysis; Hematology; Hemoglobin; HIF-Inhibitor; Non-dialysis; Nephrology; Roxadustat
This article informs the reader of the current information available on a novel therapeutic agent and new class of drug for the treatment of anemia. The data show promising results for alternative erythropoietin-stimulating agents and offers a time line of when Phase III data will be available. The information on this new drug and new drug class will change how nephrologists approach treating anemia within their patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据